To share a link to this page with a friend, colleague, or family member, please complete the form below:
E-mail addresses entered on this page will be used solely for the purpose of sending an e-card. Endo Pharmaceuticals and companies working with Endo Pharmaceuticals will not share your personal and medical information with any third parties, such as outside mailing lists. To remove yourself from future contact from Endo Pharmaceuticals, e-mail the .
Privacy/Legal
Please complete both e-mail fields with valid addresses.
E-mail addresses entered on this page will be used solely for the purpose of sending an e-card. Endo Pharmaceuticals and companies working with Endo Pharmaceuticals will not share your personal and medical information with any third parties, such as outside mailing lists. To remove yourself from future contact from Endo Pharmaceuticals, e-mail the .
Privacy/Legal
Thank you for sending an e-card about OPANA.com. Your e-card has been sent and the recipient(s) should receive an e-mail notification shortly.
Close
Close
Struggling to find pain control that meets your needs and your patients' needs?
OPANA® ER: Pain control that satisfied patients and physicians
Global ratings for opioid-experienced patients
In a 12-week trial in 142 opioid-experienced patients with moderate to severe chronic low back pain1*
80% of patients randomized to OPANA ER rated OPANA ER as "excellent", "very good", or "good" at the final visit, compared with 33% of patients randomized to placebo (P<0.0001)2
84% of physicians rated OPANA ER as "excellent", "very good", or "good" at the final visit, compared with 27% for placebo (P<0.0001)3
† Percentages do not add up to 100% due to rounding
Important Safety Information
- The most common adverse drug reactions (≥10%) in all clinical trials for OPANA ER were nausea, constipation, dizziness (excluding vertigo), vomiting, pruritus, somnolence, headache, increased sweating, and sedation
- OPANA ER contains oxymorphone, which is a morphine-like opioid agonist and a Schedule II controlled substance, with an abuse liability similar to other opioid analgesics
References
- Hale ME, Ahdieh H, Ma T, Rauck R. Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: a 12-week, randomized, double-blind, placebo-controlled study. J Pain. 2007;8(2):175-184.
- Data on file, DOF-OP-05, Endo Pharmaceuticals. Chadds Ford, Pa.
- Data on file, DOF-OP-04, Endo Pharmaceuticals. Chadds Ford, Pa.